For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Treatment Study for Patients with Metastatic Castration Resistant Prostate Cancer

Clinical Trial Title: 
A phase 1b/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide or abiraterone/prednisone in patients with metastatic castration resistant prostate cancer.
Clinical Trial Protocol ID: 
18011003
Clinical Trial Investigator Name: 
Timothy M. Kuzel, MD
Clinical Trial Protocol Description: 

This is a two-arm, open label phase 1b/2 study with an oral administration of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone in male patients with metastatic castration resistant prostate cancer. This study is designed to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) based on safety, tolerability, pharmacokinetic, and efficacy profiles of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone.

Following determination of MTD and RP2D will proceed to phase 2. Patients in phase 2 will receive CPI-1205 at the RP2D in combination with either enzalutamide or abiraterone/prednisone vs either enzalutamide or abiraterone/prednisone as a control arm.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have a life expectancy of at least 12 weeks.
  • Have histologically or cytologically confirmed adenocarcinoma of the prostate.
  • Have progressive disease in the setting of medical or surgical castration (i.e. CRPC).
  • Have documented metastatic disease.

You will be excluded from the study if any of the following criteria apply to you:

  • Have known symptomatic brain metastases.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Genitourinary Cancers
Contact Phone: 
(312) 942-5526
Contact Name: 
Pam Sroka, BS, MT(ASCP), BSN, RN, CCRC